Balyasny Asset Management L.P.

Position in SPRY — ARS Pharmaceuticals, Inc.

CIK 1218710 Chicago, IL

Position in SPRY

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$495,868

-$1,978,140 QoQ

Shares Held

61,752

-74.9% QoQ

Ownership

0.062%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Dec 2022

10 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Mar 31, 2026

Balyasny Asset Management L.P. holds $2,162,785,356 across 177 Biotechnology names. SPRY ranks #151 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	TERN	Terns Pharmaceuticals, Inc.	2,779,445	$146,532,340
2	ERAS	Erasca, Inc.	5,143,985	$83,229,677
3	TNGX	Tango Therapeutics, Inc.	3,826,659	$80,053,706
4	APLS	Apellis Pharmaceuticals, Inc.	1,917,501	$77,141,065
5	BMRN	Biomarin Pharmaceutical Inc	1,362,752	$76,981,860
6	CYTK	Cytokinetics Inc	992,545	$65,418,640
7	DAWN	Day One Biopharmaceuticals, Inc.	2,625,235	$56,285,038
8	FOLD	AMICUS THERAPEUTICS, INC.	3,827,513	$55,345,837

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$495,868	61,752	-74.9%	Shares	Sole	2026-05-15
2025-09-30	$2,474,008	246,170	-25.2%	Shares	Sole	2025-11-14
2025-06-30	$5,742,323	329,073	+92.3%	Shares	Sole	2025-08-14
2025-03-31	$2,152,739	171,124	-50.4%	Shares	Sole	2025-05-15
2024-12-31	$3,639,127	344,941	+1431.8%	Shares	Sole	2025-02-14
2024-09-30	$326,511	22,518	-14.5%	Shares	Sole	2024-11-14
2024-06-30	$224,110	26,335	-13.5%	Shares	Sole	2024-08-14
2024-03-31	$311,107	30,441	+74.6%	Shares	Sole	2024-05-13
2023-12-31	$95,565	17,439	+53.9%	Shares	Sole	2024-02-14
2022-12-31	$96,627	11,328	—	Shares	Sole	2023-02-14
No filing history on record for this holder in this stock.